Can-Fite BioPharma Ltd. Files 6-K for June 30, 2024

Ticker: CANF · Form: 6-K · Filed: Aug 29, 2024 · CIK: 1536196

Can-Fite Biopharma LTD. 6-K Filing Summary
FieldDetail
CompanyCan-Fite Biopharma LTD. (CANF)
Form Type6-K
Filed DateAug 29, 2024
Risk Levellow
Pages2
Reading Time2 min
Sentimentneutral

Sentiment: neutral

Topics: financial-results, 6-k, foreign-private-issuer

Related Tickers: CANF

TL;DR

Can-Fite BioPharma dropped its Q2 2024 financials in a 6-K filing.

AI Summary

Can-Fite BioPharma Ltd. filed a Form 6-K on August 29, 2024, reporting its financial results for the period ending June 30, 2024. The filing includes financial statements and other information relevant to its status as a foreign private issuer. The company is incorporated in Israel and its fiscal year ends on December 31.

Why It Matters

This filing provides investors with updated financial information for Can-Fite BioPharma, crucial for assessing the company's performance and financial health.

Risk Assessment

Risk Level: low — This is a routine financial filing (6-K) and does not contain new material events or significant financial changes.

Key Numbers

Key Players & Entities

FAQ

What type of report is Can-Fite BioPharma Ltd. filing?

Can-Fite BioPharma Ltd. is filing a Form 6-K, which is a Report of Foreign Private Issuer.

What is the reporting period for this filing?

The Conformed Period of Report is June 30, 2024.

When was this Form 6-K filed with the SEC?

This Form 6-K was filed on August 29, 2024.

Where is Can-Fite BioPharma Ltd. headquartered?

Can-Fite BioPharma Ltd.'s principal executive offices are located at 26 Ben Gurion Street, Ramat Gan, Israel.

Does Can-Fite BioPharma Ltd. file annual reports under Form 20-F or 40-F?

Yes, Can-Fite BioPharma Ltd. files annual reports under Form 20-F, as indicated by the checkmark next to it.

Filing Stats: 475 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-08-29 08:46:20

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: August 29, 2024 By: /s/ Motti Farbstein Motti Farbstein Chief Executive Officer and Chief Financial Officer 3

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing